1. A resident notes that physiologically secreted insulin reaches the liver first through the portal vein, whereas subcutaneous insulin reaches muscle and fat first. Integrating hepatic first-pass extraction with subcutaneous pharmacokinetics, which statement best explains why subcutaneous insulin regimens predispose to peripheral hypoglycemia?
A) Subcutaneous insulin is delivered preferentially to the portal vein, reproducing the physiological hepatic-to-peripheral gradient and eliminating hypoglycemia risk
B) Because the liver extracts none of the secreted insulin, portal and peripheral concentrations are equal, so the route of delivery has no metabolic consequence
C) Subcutaneous delivery bypasses portal first-pass extraction and presents insulin to peripheral tissues before the liver, so peripheral concentrations must be raised to achieve adequate hepatic glucose-output suppression, which predisposes to peripheral hypoglycemia
D) Subcutaneous insulin suppresses hepatic glucose output so strongly that peripheral tissues receive almost no insulin, preventing hypoglycemia
E) Peripheral hypoglycemia from subcutaneous insulin occurs only because the kidney clears insulin faster after subcutaneous than after portal delivery
ANSWER: C
Rationale:
Endogenous insulin enters the portal vein, and the liver extracts roughly 50 to 60 percent on first pass, creating hepatic concentrations two- to fourfold higher than peripheral concentrations; this gradient lets the highly insulin-sensitive suppression of hepatic glucose output occur without driving peripheral hypoglycemia. Subcutaneous insulin bypasses portal delivery and reaches muscle and fat before the liver, so peripheral concentrations must be raised to obtain adequate hepatic effect, an inherent limitation that predisposes to peripheral hypoglycemia.
Option A: Option A is incorrect because subcutaneous delivery reaches the systemic circulation first and specifically does not reproduce portal delivery.
Option B: Option B is incorrect because the liver extracts a substantial fraction of secreted insulin, which is exactly what creates the portal-peripheral gradient.
Option D: Option D is incorrect because subcutaneous insulin reaches peripheral tissues in high concentration, which is the source of hypoglycemia rather than a protection against it.
Option E: Option E is incorrect because the route-dependent hypoglycemia reflects loss of the portal gradient, not a difference in renal clearance between routes.
2. A patient injects rapid-acting insulin into the thigh, then immediately goes for a run and later takes a hot shower, and develops hypoglycemia sooner than expected. Integrating the determinants of subcutaneous absorption with this scenario, which explanation is most accurate?
A) Exercise and heat slow absorption, so the hypoglycemia must be due to an unrelated cause
B) The thigh has the fastest absorption of any site, which alone explains the rapid effect regardless of activity
C) Hot water denatures the injected insulin, paradoxically increasing its potency
D) Exercise lowers glucose only by increasing hepatic glucose output, unrelated to insulin absorption
E) Exercising the injected limb and applying heat both increase local blood flow at the injection site, accelerating insulin absorption and precipitating earlier, more pronounced hypoglycemia
ANSWER: E
Rationale:
Local blood flow at the injection site is a major determinant of absorption rate: heat application, exercise of the injected limb, and massage all increase blood flow and accelerate absorption, which can precipitate hypoglycemia. Both running with the injected leg and a subsequent hot shower raise local blood flow, producing an earlier and larger insulin effect than anticipated.
Option A: Option A is incorrect because heat and exercise of the injected limb speed, not slow, absorption.
Option B: Option B is incorrect because the thigh is actually among the slower absorption sites, so site alone does not explain accelerated absorption; the increased local blood flow does.
Option C: Option C is incorrect because hot water does not denature subcutaneously deposited insulin to increase potency; it accelerates absorption by raising blood flow.
Option D: Option D is incorrect because exercise also increases insulin-independent glucose uptake and, when the injected limb is exercised, accelerates absorption, rather than acting only through hepatic glucose output.
3. A patient who has injected into the same abdominal site for years, producing palpable lipohypertrophy, is counseled to rotate to healthy tissue. The same dose is given into a fresh site and the patient becomes hypoglycemic. Integrating the absorption properties of lipohypertrophic versus healthy tissue, which statement best explains this outcome?
A) Healthy tissue absorbs insulin more slowly than lipohypertrophic tissue, so the dose should have been increased
B) Lipohypertrophic tissue absorbs insulin slowly and erratically, so switching to healthy, well-vascularized tissue sharply increases absorption; without an anticipatory dose reduction this produces hypoglycemia
C) Lipohypertrophy and healthy tissue absorb insulin identically, so the hypoglycemia is unrelated to the site change
D) The fresh site destroyed part of the insulin, which somehow increased the systemic effect
E) Lipohypertrophic tissue absorbs insulin faster, so moving to healthy tissue should have reduced the effect and raised glucose
ANSWER: B
Rationale:
Lipohypertrophic tissue is poorly vascularized and absorbs insulin slowly and erratically, so a dose that seemed adequate there was partly blunted by delayed absorption. Switching to healthy, well-vascularized tissue sharply increases absorption, so the same dose now delivers more active insulin; this is why rotation to healthy sites must be paired with an anticipatory dose reduction to avoid hypoglycemia.
Option A: Option A is incorrect because healthy tissue absorbs faster, not slower, so the dose should be reduced rather than increased.
Option C: Option C is incorrect because the two tissues absorb very differently, which is the basis for the hypoglycemia.
Option D: Option D is incorrect because the fresh site does not destroy insulin; it absorbs it more completely and rapidly.
Option E: Option E is incorrect because lipohypertrophic tissue absorbs more slowly, not faster, so the direction of the effect is inverted.
4. A patient asks whether insulin glargine can be drawn up in the same syringe as a rapid-acting analog to reduce the number of injections. Integrating glargine's formulation chemistry with insulin mixing principles, what is the best response?
A) Yes, glargine mixes freely with any insulin because it is fully soluble in the vial
B) Yes, mixing is encouraged because the acidic glargine raises the pH of the rapid-acting analog and speeds its absorption
C) It does not matter, because all insulins share the same pH and can be combined without consequence
D) No, glargine should not be mixed in a syringe with other insulins because its acidic, pH 4 formulation is incompatible with neutral-pH preparations and mixing can alter the time-action profile of one or both insulins
E) No, but only because glargine is a suspension that would clog the needle
ANSWER: D
Rationale:
Insulin glargine is formulated at an acidic pH (about 4) so that it stays fully soluble in the vial but precipitates as microprecipitates upon injection into neutral subcutaneous tissue. Combining it in a syringe with a neutral-pH preparation such as a rapid-acting analog is incompatible and can alter the time-action profile of one or both insulins, so glargine should not be mixed.
Option A: Option A is incorrect because glargine's solubility in its own acidic vial does not make it compatible for mixing with neutral-pH insulins.
Option B: Option B is incorrect because mixing does not beneficially raise the analog's pH; the pH incompatibility is the very reason not to mix.
Option C: Option C is incorrect because insulins do not all share the same pH; glargine is acidic while most others are neutral.
Option E: Option E is incorrect because glargine is a clear solution in the vial, not a suspension, so the reason not to mix is pH incompatibility, not needle clogging.
5. A patient with declining renal function on a previously stable insulin regimen skips lunch and develops a prolonged, severe hypoglycemic episode. Integrating the effect of renal impairment on insulin clearance with the effect of a missed meal, which explanation best accounts for the severity?
A) Reduced renal insulin clearance prolongs insulin action, and the missed meal removes expected carbohydrate, so the two effects compound to produce a deeper and more prolonged hypoglycemic episode
B) Renal impairment increases insulin clearance, so the episode must be due entirely to the missed meal
C) A missed meal raises insulin requirements, so hypoglycemia from skipping a meal is physiologically impossible
D) Renal impairment and meal timing act on independent systems that cannot combine to worsen hypoglycemia
E) The kidney plays no role in insulin clearance, so renal function is irrelevant to this episode
ANSWER: A
Rationale:
The kidney accounts for a substantial share of peripheral insulin clearance, so declining renal function reduces clearance and prolongs insulin action, often warranting dose reduction. When this is combined with a missed meal, which removes the carbohydrate the dose anticipated, the prolonged insulin exposure and the carbohydrate deficit compound to produce a deeper and more prolonged hypoglycemic episode.
Option B: Option B is incorrect because renal impairment reduces, not increases, insulin clearance, so it contributes to rather than being irrelevant to the episode.
Option C: Option C is incorrect because a missed meal lowers available glucose against an unchanged insulin dose and is a recognized precipitant of hypoglycemia, not a protection.
Option D: Option D is incorrect because reduced clearance and reduced carbohydrate intake both push glucose downward and therefore do combine.
Option E: Option E is incorrect because the kidney is a major site of insulin clearance, so renal function is directly relevant.
6. A student asks why type 1 diabetes is managed with a basal-bolus regimen rather than a single insulin given once daily. Integrating the two physiological roles of insulin secretion, which statement best explains the rationale?
A) Basal-bolus therapy is used only to increase the number of injections for adherence monitoring, not for any physiological reason
B) A single daily injection of rapid-acting insulin fully reproduces both fasting and postprandial insulin needs
C) Basal insulin provides continuous suppression of hepatic glucose output between meals and overnight, while bolus insulin at meals covers postprandial glucose excursions; basal-bolus therapy matches insulin pharmacokinetics to these two distinct physiological roles
D) Basal insulin is given only to cover meals, while bolus insulin suppresses overnight hepatic glucose output
E) In type 1 diabetes, endogenous secretion is intact, so only a small basal dose is needed and bolus insulin is unnecessary
ANSWER: C
Rationale:
Physiological insulin secretion has two roles: a continuous basal output that restrains hepatic glucose production between meals and overnight, and meal-related surges that cover postprandial glucose. Basal-bolus therapy reproduces this by combining a basal insulin for between-meal and overnight suppression with mealtime bolus insulin for postprandial excursions, matching insulin pharmacokinetics to each role.
Option A: Option A is incorrect because the regimen is built on physiology, not on monitoring convenience.
Option B: Option B is incorrect because a single rapid-acting injection cannot provide continuous overnight basal coverage.
Option D: Option D is incorrect because it inverts the roles: basal covers the fasting/overnight period and bolus covers meals.
Option E: Option E is incorrect because type 1 diabetes is defined by absent endogenous insulin secretion, so both basal and bolus replacement are required.
7. A patient on basal-bolus therapy has consistently elevated fasting (pre-breakfast) glucose but satisfactory post-meal glucose throughout the day. Integrating the roles of basal and bolus insulin with glucose-pattern interpretation, which adjustment is most appropriate?
A) Increase the mealtime bolus doses, because elevated fasting glucose reflects inadequate postprandial coverage
B) Increase the basal insulin dose, because persistently elevated fasting glucose with satisfactory postprandial values indicates insufficient basal coverage of overnight hepatic glucose output
C) Decrease the basal insulin dose, because high fasting glucose indicates basal overtreatment
D) Add a second bolus at bedtime, because fasting hyperglycemia is a postprandial phenomenon
E) Make no change, because fasting glucose does not respond to insulin adjustment
ANSWER: B
Rationale:
Persistently elevated fasting glucose with satisfactory postprandial values points to insufficient basal insulin, since basal insulin governs overnight and between-meal hepatic glucose output; the appropriate response is to increase the basal dose.
Option A: Option A is incorrect because the postprandial values are already satisfactory, so increasing the bolus would not address fasting hyperglycemia and could cause post-meal hypoglycemia.
Option C: Option C is incorrect because high fasting glucose indicates insufficient, not excessive, basal coverage, so reducing the basal dose would worsen it.
Option D: Option D is incorrect because fasting hyperglycemia reflects basal deficiency rather than a postprandial phenomenon requiring an extra bolus.
Option E: Option E is incorrect because fasting glucose is precisely what basal insulin titration targets.
8. A patient with type 2 diabetes mellitus on intensifying insulin therapy is gaining weight, which is worsening insulin resistance and escalating insulin requirements. Integrating the mechanism of insulin-associated weight gain with evidence-based mitigation, which addition best attenuates further weight gain while maintaining glycemic control?
A) Increasing the insulin dose further, since more insulin will independently reduce weight
B) Adding a sulfonylurea, since it reliably promotes weight loss alongside insulin
C) Adding a thiazolidinedione, since it counteracts insulin-related weight gain
D) Switching all insulin to NPH (neutral protamine Hagedorn), since intermediate-acting insulin does not cause weight gain
E) Adding a GLP-1 (glucagon-like peptide-1) receptor agonist or an SGLT-2 (sodium-glucose cotransporter-2) inhibitor, both of which attenuate insulin-associated weight gain while maintaining glycemic control and have cardiovascular outcome trial support in type 2 diabetes
ANSWER: E
Rationale:
Insulin intensification drives weight gain through reversal of glycosuria, enhanced lipogenesis and suppressed lipolysis, defensive eating from hypoglycemia, and reduced energy expenditure; this weight gain worsens insulin resistance and escalates requirements. Adding a GLP-1 (glucagon-like peptide-1) receptor agonist or an SGLT-2 (sodium-glucose cotransporter-2) inhibitor attenuates insulin-associated weight gain while maintaining control, and both combinations have cardiovascular outcome trial support in type 2 diabetes.
Option A: Option A is incorrect because more insulin promotes further weight gain rather than reducing it.
Option B: Option B is incorrect because sulfonylureas tend to cause weight gain and hypoglycemia, not weight loss.
Option C: Option C is incorrect because thiazolidinediones are associated with weight gain and fluid retention rather than counteracting insulin-related weight gain.
Option D: Option D is incorrect because switching to NPH does not avoid insulin-associated weight gain, which is a class effect of insulin intensification.
9. An insulin-treated patient is started on a non-selective beta-blocker. Integrating the drug's effect on counter-regulation with its effect on hypoglycemia symptoms, which consequence should the clinician anticipate?
A) The beta-blocker blunts adrenergic warning symptoms such as tachycardia and tremor while sweating is relatively preserved, and it can prolong hypoglycemia by blunting hepatic glycogenolysis, so episodes may be both less recognizable and slower to resolve
B) The beta-blocker enhances all adrenergic warning symptoms, making hypoglycemia easier to detect
C) The beta-blocker increases hepatic glycogenolysis, so hypoglycemia resolves faster than usual
D) The beta-blocker has no interaction with insulin or glucose counter-regulation
E) The beta-blocker abolishes sweating specifically while leaving tachycardia and tremor as reliable warnings
ANSWER: A
Rationale:
Non-selective beta-blockers blunt the adrenergic warning symptoms of hypoglycemia such as tachycardia and tremor while sweating, which is cholinergically mediated, is relatively preserved; they can also prolong hypoglycemia by blunting hepatic glycogenolysis. The clinician should therefore anticipate episodes that are both harder to recognize and slower to resolve.
Option B: Option B is incorrect because the beta-blocker blunts rather than enhances adrenergic warnings.
Option C: Option C is incorrect because blocking beta receptors reduces glycogenolysis, prolonging rather than shortening hypoglycemia.
Option D: Option D is incorrect because non-selective beta-blockade clearly interacts with glucose counter-regulation and symptom perception.
Option E: Option E is incorrect because it inverts the pattern: sweating is the symptom that tends to be preserved, while tachycardia and tremor are the ones blunted.
10. A patient on insulin begins once-daily morning prednisone and now has marked afternoon and evening hyperglycemia with relatively normal morning glucose. Integrating the pharmacodynamic time course of a morning glucocorticoid dose with insulin requirements, which adjustment is most appropriate?
A) Reduce all insulin doses, because glucocorticoids lower insulin requirements
B) Increase only the overnight basal insulin, because steroid effect is greatest at night
C) Make no change, because glucocorticoids do not affect glucose
D) Anticipate higher insulin requirements that track the steroid's pharmacodynamic peak, increasing insulin coverage directed at the afternoon and evening when the morning glucocorticoid dose produces its greatest glucose elevation
E) Switch to a twice-daily glucocorticoid, because that eliminates any effect on glucose
ANSWER: D
Rationale:
Glucocorticoids raise insulin requirements in a dose- and timing-dependent way, and a morning dose produces its greatest glucose elevation in the afternoon and evening, mirroring its pharmacodynamic peak. The appropriate response is anticipatory increases in insulin directed at that interval, often a 20 to 50 percent or greater increase with attention to afternoon and evening glucose.
Option A: Option A is incorrect because glucocorticoids increase, not decrease, insulin requirements.
Option B: Option B is incorrect because a morning steroid dose elevates glucose most in the afternoon and evening, not overnight, so targeting only overnight basal would miss the peak.
Option C: Option C is incorrect because glucocorticoids clearly raise glucose and require dose adjustment.
Option E: Option E is incorrect because changing the steroid schedule does not eliminate its hyperglycemic effect and is not the appropriate management of the glucose pattern.
11. A patient with type 1 diabetes mellitus and frequent hypoglycemia now experiences episodes without warning symptoms, consistent with impaired awareness of hypoglycemia from hypoglycemia-associated autonomic failure (HAAF). Integrating the mechanism of HAAF with its management, which approach is most likely to restore hypoglycemia awareness?
A) Intentionally allowing more frequent hypoglycemia to retrain the warning system
B) Tightening glucose targets aggressively to lower the average glucose
C) Scrupulously avoiding hypoglycemia for several weeks, including a temporary upward revision of glucose targets, combined with real-time CGM (continuous glucose monitoring) with threshold alerts, which can partly restore the lowered counter-regulatory and symptom thresholds
D) Discontinuing all insulin until awareness returns
E) Adding a non-selective beta-blocker to amplify adrenergic warning symptoms
ANSWER: C
Rationale:
Recurrent hypoglycemia lowers the glucose threshold for counter-regulation and neurogenic symptoms (HAAF), producing impaired awareness. Because the defect is driven by recurrent hypoglycemia, scrupulously avoiding hypoglycemia for several weeks, including a temporary upward revision of glucose targets, can partly restore awareness; real-time CGM (continuous glucose monitoring) with threshold alerts provides an alarm independent of symptoms.
Option A: Option A is incorrect because more hypoglycemia deepens HAAF rather than retraining the warning system.
Option B: Option B is incorrect because aggressively tightening targets increases hypoglycemia exposure and worsens awareness.
Option D: Option D is incorrect because stopping all insulin is unsafe in type 1 diabetes and is not the management of impaired awareness.
Option E: Option E is incorrect because a non-selective beta-blocker blunts rather than amplifies adrenergic warnings and would further impair recognition.
12. An insulin-treated patient drinks heavily at dinner and experiences hypoglycemia several hours later overnight; a caregiver's attempt to treat with glucagon is relatively ineffective. Integrating alcohol's effect on hepatic glucose handling with the mechanism of glucagon, which explanation is most accurate?
A) Alcohol causes immediate hyperglycemia, so the overnight hypoglycemia must be unrelated to drinking
B) Alcohol suppresses hepatic gluconeogenesis, producing delayed hypoglycemia typically 4 to 8 hours after ingestion, and glucagon is relatively ineffective in this setting because its glucose-raising action depends on hepatic glycogen mobilization, which is compromised when glycogen is depleted and gluconeogenesis is blocked
C) Alcohol accelerates glucagon's action, so the poor response indicates the glucagon was expired
D) Alcohol increases hepatic glucose output, so glucagon should have worked normally
E) Glucagon failed only because it was given subcutaneously rather than orally
ANSWER: B
Rationale:
Alcohol suppresses hepatic gluconeogenesis (in part by consuming NAD+ during ethanol oxidation), producing hypoglycemia that is characteristically delayed 4 to 8 hours after ingestion. Glucagon raises glucose mainly by mobilizing hepatic glycogen, so it is relatively ineffective when glycogen stores are depleted and gluconeogenesis is simultaneously blocked, as in this scenario; intravenous dextrose is the more reliable treatment.
Option A: Option A is incorrect because alcohol predisposes to delayed hypoglycemia rather than immediate hyperglycemia.
Option C: Option C is incorrect because alcohol does not accelerate glucagon's action, and the poor response reflects depleted glycogen rather than an expired product.
Option D: Option D is incorrect because alcohol suppresses, not increases, hepatic glucose output.
Option E: Option E is incorrect because glucagon is appropriately given parenterally and is ineffective here because of depleted glycogen, not the route.
13. A pregnant patient with type 1 diabetes mellitus has required steadily increasing insulin doses through the third trimester. Integrating the physiology of placental hormones with peripartum dosing, what change should be anticipated immediately after delivery?
A) Insulin requirements fall abruptly with delivery of the placenta because the placental hormones driving insulin resistance are removed, so the dose must be reduced sharply right after delivery to avoid hypoglycemia
B) Insulin requirements continue to rise after delivery, so the dose should be increased further postpartum
C) Insulin requirements remain at the third-trimester level indefinitely after delivery, so no change is needed
D) Insulin requirements fall slowly over several months, so no immediate adjustment is warranted
E) Delivery has no effect on insulin requirements because placental hormones persist for weeks
ANSWER: A
Rationale:
Placental hormones (human placental lactogen, cortisol, progesterone, prolactin) produce progressive insulin resistance, so requirements often rise substantially through the second and third trimesters. With delivery of the placenta these hormones are abruptly removed, and insulin requirements fall sharply, so the dose must be reduced markedly right after delivery to prevent hypoglycemia.
Option B: Option B is incorrect because requirements drop rather than continue rising once the placenta is delivered.
Option C: Option C is incorrect because the third-trimester elevation does not persist after the placenta is removed.
Option D: Option D is incorrect because the fall is abrupt at delivery, not a gradual months-long decline, so immediate adjustment is needed.
Option E: Option E is incorrect because the placental hormone effect resolves rapidly once the placenta is delivered rather than persisting for weeks.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.